Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior

Human Molecular Genetics

Volumn 25, Issue 24, 2016, Pages 5472-5482

  Cornelis, Marilyn C ^a   Kacprowski, Tim ^b,c   Menni, Cristina ^d   Gustafsson, Stefan ^e   Pivin, Edward ^f   Adamski, Jerzy ^g,h,i   Artati, Anna ^g   Eap, Chin B ^j,k   Ehret, Georg ^l,m   Friedrich, Nele ^b,c   Ganna, Andrea ^n,o   Guessous, Idris ^b,f,l,p   Homuth, Georg ^b   Lind, Lars ^e   Magnusson, Patrik K ^q   Mangino, Massimo ^d   Pedersen, Nancy L ^q   Pietzner, Maik ^b,c   Suhre, Karsten ^g,r   Völzke, Henry ^b   Bochud, Murielle ^f   Spector, Tim D ^d   Grabe, Hans J ^b   Ingelsson, Erik ^e,s   Burnier, Michel ^t   Devuyst, Olivier ^u   Martin, Pierre Yves ^l   Mohaupt, Markus ^v   Paccaud, Fred ^f   Pechere Bertschi, Antoinette ^l   Vogt, Bruno ^v   Ackermann, Daniel ^v   Ponte, Belen ^l   Pruijm, Menno ^t   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^j Unit of Biochemistry and Clinical Psychopharmacology   (Switzerland)

^k UNIVERSITY OF GENEVA   (Switzerland)

^l GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^p EMORY UNIVERSITY   (United States)

^q KAROLINSKA INSTITUTE   (Sweden)

^r WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^s STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^u UNIVERSITY OF ZURICH   (Switzerland)

^v UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CAFFEINE DERIVATIVE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE; 1,7-DIMETHYLXANTHINE; AHR PROTEIN, HUMAN; AROMATIC HYDROCARBON RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CD83 ANTIGEN; COFFEE; CYP1A2 PROTEIN, HUMAN; CYP2A6 PROTEIN, HUMAN; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ABCG2 GENE; ARTICLE; BLOOD LEVEL; CAFFEINE METABOLISM; CHROMOSOME 15Q; CHROMOSOME 19Q; CHROMOSOME 6P; CHROMOSOME 7P; CYP1A2 GENE; CYP2A6 GENE; DIETARY INTAKE; GENE; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HUMAN; METABOLISM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CAUCASIAN; COFFEE; FEMALE; GENETICS; MALE;

ANTIGENS, CD; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAFFEINE; COFFEE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2A6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOGLOBULINS; MALE; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ARYL HYDROCARBON; THEOBROMINE; THEOPHYLLINE;

EID: 85016000379     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw334     Document Type: Article

References (58)

1. Fredholm, B.B., Battig, K., Holmen, J., Nehlig, A. and Zvartau, E.E. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev., 51, 83-133.
2. Heckman, M.A., Weil, J. and Gonzalez de Mejia, E. (2010) Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. J. Food Sci., 75, R77-R87.
3. Gu, L., Gonzalez, F.J., Kalow, W. and Tang, B.K. (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics, 2, 73-77.
4. Cornelis, M.C. (2015) Toward systems epidemiology of coffee and health. Curr. Opin. Lipidol., 26, 20-29.
5. Thorn, C.F., Aklillu, E., McDonagh, E.M., Klein, T.E. and Altman, R.B. (2012) PharmGKB summary: caffeine pathway. Pharmacogenet. Genomics, 22, 389.
6. Gunes, A. and Dahl, M.L. (2008) Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 9, 625-637.
7. Thorn, C.F., Aklillu, E., Klein, T.E. and Altman, R.B. (2012) PharmGKB summary: very important. Pharmacogene information for CYP1A2. Pharmacogenet. Genomics, 22, 73-77.
8. Perera, V., Gross, A.S. and McLachlan, A.J. (2012) Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr. Drug Metab., 13, 667-678.
9. Perera, V., Gross, A.S. and McLachlan, A.J. (2012) Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin. Pharmacol. Ther., 92, 511-519.
10. Cornelis, M.C., Monda, K.L., Yu, K., Paynter, N., Azzato, E.M., Bennett, S.N., Berndt, S.I., Boerwinkle, E., Chanock, S., Chatterjee, N. et al. (2011) Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet., 7, e1002033.
11. Coffee and Caffeine Genetics Consortium, Cornelis, M.C., Byrne, E.M., Esko, T., Nalls, M.A., Ganna, A., Paynter, N., Monda, K.L., Amin, N., Fischer, K. et al. (2015) Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol. Psychiatry, 20, 647-656.
12. Shin, S.Y., Fauman, E.B., Petersen, A.K., Krumsiek, J., Santos, R., Huang, J., Arnold, M., Erte, I., Forgetta, V., Yang, T.P. et al. (2014) An atlas of genetic influences on human blood metabolites. Nat. Genet., 46, 543-550.
13. Suhre, K., Shin, S.Y., Petersen, A.K., Mohney, R.P., Meredith, D., Wagele, B., Altmaier, E., Deloukas, P., Erdmann, J., Grundberg, E. et al. (2011) Human metabolic individuality in biomedical and pharmaceutical research. Nature, 477, 54-60.
14. Klein, K., Winter, S., Turpeinen, M., Schwab, M. and Zanger, U.M. (2010) Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. Front. Pharmacol., 1, 129.
15. Beischlag, T.V., Luis Morales, J., Hollingshead, B.D. and Perdew, G.H. (2008) The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expr., 18, 207-250.
16. Kot, M. and Daniel, W.A. (2008) The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNAexpressed P450s including CYP2C isoforms. Biochem. Pharmacol., 76, 543-551.
17. Le Vee, M., Jouan, E. and Fardel, O. (2010) Involvement of aryl hydrocarbon receptor in basal and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin-induced expression of target genes in primary human hepatocytes. Toxicol. In Vitro, 24, 1775-1781.
18. Kimura, M., Yamazaki, H., Fujieda, M., Kiyotani, K., Honda, G., Saruwatari, J., Nakagawa, K., Ishizaki, T. and Kamataki, T. (2005) CYP2A6 is a principle enzyme involved in hydroxylation of 1, 7-dimethylxanthine, a main caffeine metabolite in humans. Drug Metab. Dispos., 33, 1361-1366.
19. Campbell, M.E., Grant, D.M., Inaba, T. and Kalow, W. (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarboninducible cytochrome(s) P-450 in human liver microsomes. Drug Metab. Dispos, 15, 237-249.
20. Begas, E., Kouvaras, E., Tsakalof, A., Papakosta, S. and Asprodini, E.K. (2007) In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed. Chromatogr., 21, 190-200.
21. Denaro, C.P., Wilson, M., Jacob, P. and Benowitz, N.L. (1996) Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin. Pharmacol. Ther, 59, 284-296.
22. Djordjevic, N., Carrillo, J.A., Gervasini, G., Jankovic, S. and Aklillu, E. (2010) In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur. J. Clin. Pharmacol., 66, 571-578.
23. Benowitz, N.L., Swan, G.E., Jacob, P., 3rd, Lessov-Schlaggar, C.N. and Tyndale, R.F. (2006) CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther., 80, 457-467.
24. Dempsey, D., Tutka, P., Jacob, P., 3rd, Allen, F., Schoedel, K., Tyndale, R.F. and Benowitz, N.L. (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther., 76, 64-72.
25. Loukola, A., Buchwald, J., Gupta, R., Palviainen, T., Hällfors, J., Tikkanen, E., Korhonen, T., Ollikainen, M., Sarin, A.P. and Ripatti, S. (2015) A genome-wide association study of a biomarker of nicotine metabolism. PLoS Genet., 11, e1005498.
26. Raunio, H. and Rahnasto-Rilla, M. (2012) CYP2A6: genetics, structure, regulation, and function. Drug Metabol. Drug Interact., 27, 73-88.
27. Bergen, A.W., Michel, M., Nishita, D., Krasnow, R., Javitz, H.S., Conneely, K.N., Lessov-Schlaggar, C.N., Hops, H., Zhu, A.Z. and Baurley, J.W. (2015) Drugmetabolizing enzyme and transporter gene variation, nicotine metabolism, prospective abstinence, and cigarette consumption. PLoS One, 10, e0126113.
28. Thorgeirsson, T.E., Gudbjartsson, D.F., Surakka, I., Vink, J.M., Amin, N., Geller, F., Sulem, P., Rafnar, T., Esko, T., Walter, S. et al. (2010) Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet., 42, 448-453.
29. Hu, L., Zhuo, W., He, Y.J., Zhou, H.H. and Fan, L. (2012) Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenet. Genomics, 22, 812-819.
30. Giacomini, K., Balimane, P., Cho, S., Eadon, M., Edeki, T., Hillgren, K., Huang, S.M., Sugiyama, Y., Weitz, D. and Wen, Y. (2013) International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin. Pharmacol. Ther., 94, 23-26.
31. Klaassen, C.D. and Aleksunes, L.M. (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev., 62, 1-96.
32. Arnaud, M.J. (2011) Pharmacokinetic and metabolism of natural methylxanthines in animal and man. In Fredholm, B. (ed.), Methylxanthines. Springer, pp. 33-92.
33. Vlaming, M.L., Lagas, J.S. and Schinkel, A.H. (2009) Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev., 61, 14-25.
34. McCall, A.L., Millington, W.R. and Wurtman, R.J. (1982) Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport. Life Sci., 31, 2709-2715.
35. Shyr, M.H., Lin, L.C., Chang, C.H., Wu, Y.T., Hsieh, Y.J. and Tsai, T.H. (2006) Hepatobiliary excretion and brain distribution of caffeine in rats using microdialysis. Anal. Chim. Acta., 566, 265-270.
36. Burdett, T., Hall, P., Hastings, E., Hindorf, L., Junkins, H.A., Klemm, A., MacArthur, J., Manolio, T., Morales, J., Parkinson, H. et al. (2016) The NHGRI-EBI Catalog of published genome-wide association studies, www.ebi.ac.uk/gwas, accessed April 2016.
37. Lindskog, M., Svenningsson, P., Pozzi, L., Kim, Y., Fienberg, A.A., Bibb, J.A., Fredholm, B.B., Nairn, A.C., Greengard, P. and Fisone, G. (2002) Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature, 418, 774-778.
38. Zanger, U.M. and Schwab, M. (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther., 138, 103-141.
39. Lind, L., Fors, N., Hall, J., Marttala, K. and Stenborg, A. (2005) A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler. Thromb. Vasc. Biol., 25, 2368-2375.
40. Volzke, H., Alte, D., Schmidt, C.O., Radke, D., Lorbeer, R., Friedrich, N., Aumann, N., Lau, K., Piontek, M., Born, G. et al. (2011) Cohort profile: the study of health in Pomerania. Int. J. Epidemiol., 40, 294-307.
41. Ponte, B., Pruijm, M., Ackermann, D., Vuistiner, P., Eisenberger, U., Guessous, I., Rousson, V., Mohaupt, M.G., Alwan, H., Ehret, G. et al. (2014) Reference values and factors associated with renal resistive index in a family-based population study. Hypertension, 63, 136-142.
42. Magnusson, P.K., Almqvist, C., Rahman, I., Ganna, A., Viktorin, A., Walum, H., Halldner, L., Lundstrom, S., Ullen, F., Langstrom, N. et al. (2013) The Swedish Twin Registry: establishment of a biobank and other recent developments. Twin. Res. Hum. Genet., 16, 317-329.
43. Moayyeri, A., Hammond, C.J., Valdes, A.M. and Spector, T.D. (2013) Cohort Profile: TwinsUK and healthy ageing twin study. Int. J. Epidemiol., 42, 76-85.
44. Ingelsson, E., Sundstrom, J., Arnlov, J., Zethelius, B. and Lind, L. (2005) Insulin resistance and risk of congestive heart failure. Jama, 294, 334-341.
45. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A. and Reich, D. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet., 38, 904-909.
46. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet., 81, 559-575.
47. Fuchsberger, C., Abecasis, G.R. and Hinds, D.A. (2015) minimac2: faster genotype imputation. Bioinformatics, 31, 782-784.
48. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. and Abecasis, G.R. (2012) Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet., 44, 955-959.
49. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T. and McVean, G.A. (2012) An integrated map of genetic variation from1, 092 human genomes. Nature, 491, 56-65.
50. UK Biobank Coordinating Centre. (2007) UK Biobank: Protocol for a large-scale prospective epidemiological resource, http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf; date last accessed August 2016.
51. UK Biobank Coordinating Centre. (2006) UK Biobank touchscreen questionnaire: final version, http://biobank.ctsu.ox. ac.uk/crystal/docs/TouchscreenQuestionsMainFinal.pdf; date last accessed August 2016.
52. UK biobank Coordinating Centre. (2014) UK Biobank Axiom Array, http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/UK-Biobank-Axiom-Array-Content-Summary-2014. pdf; date last accessed August 2016.
53. UK Biobank Coordinating Centre. (2015) Genotype imputation and genetic association studies using UK Biobank data, http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi? id=157020; date last accessed August 2016.
54. Willer, C.J., Li, Y. and Abecasis, G.R. (2010) METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics, 26, 2190-2191.
55. Segre, A.V., Groop, L., Mootha, V.K., Daly, M.J. and Altshuler, D. (2010) Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet., 6, e1001058.
56. Liu, J.Z., McRae, A.F., Nyholt, D.R., Medland, S.E., Wray, N.R., Brown, K.M., Hayward, N.K., Montgomery, G.W., Visscher, P.M., Martin, N.G. et al. (2010) A versatile gene-based test for genome-wide association studies. Am. J. Hum. Genet., 87, 139-145.
57. Ward, L.D. and Kellis, M. (2016) HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res., 44, D877-D881.
58. UK Biobank Coordinating Centre. (2015) Genotype imputation and genetic association studies of UK Biobank, http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/imputa tion_documentation_May2015.pdf.